Publication Name	World Journal of Clinical Oncology
Manuscript ID	8734
Country	Denmark

Received	2014-01-04 14:24
Peer-Review Started	2014-01-04 19:26
First Decision by Editorial Office Director
Return for Revision	2014-02-20 20:38
Revised	2014-03-10 21:40
Publication Fee Transferred
Second Decision by Editor	2014-06-16 13:56
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-06-16 14:06
Articles in Press	2014-06-16 14:43
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-24 14:16
Publish the Manuscript Online	2014-08-01 16:16

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Biology
Manuscript Type	Topic Highlights
Article Title	C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma
Manuscript Source	Invited Manuscript
All Author List	Benedikte Jacobsen, Mette Camilla Kriegbaum, Eric Santoni-Rugiu and Michael Ploug
Funding Agency and Grant Number	Funding Agency Grant Number Copenhagen University Hospital (Rigshospitalets Forskningspuljer) he Danish National Research Foundation (Danish-Chinese Centre for Proteases and Cancer) Harboefonden, Torben og Alice Frimodts Fond Fabrikant Einar Willumsens Mindelegat Holger Rabitz and hustrus Legat Lundbeck Foundation
Corresponding Author	Michael Ploug, PhD, DSc, The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maal?es Vej 5, Room 3.3.31, 2200 Copenhagen, Denmark. m-ploug@finsenlab.dk
Key Words	LYPD3; Non-small cell lung cancer; Prognosis; Solid growth pattern; Liver kinase B1; Precursor lesions; Atypical adenomatous hyperplasia; Metaplasia; Squamous differentiation; Ly6/Urokinase-type plasminogen activator receptor
Core Tip	C4.4A is a new biomarker with potential prognostic value in pulmonary adenocarcinoma. High levels of protein expression correlate with poor patient survival and a histological growth pattern of the solid type. Recent data suggest that C4.4A is negatively regulated by the tumor suppressor liver kinase B1 (LKB1), which is inactivated in a fraction of adenocarcinomas of the lung. Such an inverse association between C4.4A and LKB1 could possibly render C4.4A a candidate predictive biomarker for therapeutic intervention targeting components of the LKB1 pathway, such as mammalian target of rapamycin.
Publish Date	2014-08-01 16:16
Citation	Jacobsen B, Kriegbaum MC, Santoni-Rugiu E, Ploug M. C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. World J Clin Oncol 2014; 5(4): 621-632
URL	http://www.wjgnet.com/2218-4333/full/v5/i4/621.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i4.621

Full Article (PDF)	WJCO-5-621.pdf
Full Article (Word)	WJCO-5-621.doc
Manuscript File	8734-Review.doc
Answering Reviewers	8734-Answering reviewers.pdf
Copyright License Agreement	8734-Copyright assignment.pdf
Peer-review Report	8734-Peer review(s).pdf
Scientific Misconduct Check	8734-CrossCheck.jpg
Scientific Editor Work List	8734-Scientific editor work list.pdf